NCT04578886View on ClinicalTrials.gov

The Effect of Guanfacine on Delirium in Critically Ill Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

February 20, 2023

Study Completion Date

April 1, 2023

Conditions
Delirium
Interventions
DRUG

Guanfacine

Guanfacine 2 mg administered at 21:00 for up to 14 days or otherwise indicated by study protocol.

DRUG

Placebo

Placebo, administered at 2100 for up to 14 days or otherwise indicated by study protocol.

Trial Locations (1)

35295

University of Alabama at Birmingham Hospital, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER